(VIANEWS) – The Market ended the session with MAAT PHARMA (MAAT.PA) jumping 10.43% to €7.20 on Monday while CAC 40 rose 0.56% to €7,413.25.
MAAT PHARMA’s last close was €6.52, 41.26% below its 52-week high of €11.10.
About MAAT PHARMA
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, MAAT PHARMA has a trailing twelve months EPS of €-1.4.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.11%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MAAT PHARMA’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
MAAT PHARMA’s stock is valued at €7.20 at 21:32 EST, way under its 52-week high of €11.10 and way above its 52-week low of €4.50.
Volatility
MAAT PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.41%, a negative 0.43%, and a positive 3.28%.
MAAT PHARMA’s highest amplitude of average volatility was 2.41% (last week), 2.90% (last month), and 3.28% (last quarter).
More news about MAAT PHARMA (MAAT.PA).
